Thus, the additional “anti-estrogen” effect of SHBG will manifest itself if the “correct” sequence of its binding, first with the cell membrane (leads to the implementation of a cascade of intracellular anti-proliferative processes), and then with free steroids, which will lead to a decrease in the number of their bioavailable forms and, accordingly, to less pronounced independent phenotypic effects in the organism (reducing the BC risk). Here, SHBG is linked to breast cancer.